Literature DB >> 11290811

Posttransplant administration of donor leukocytes induces long-term acceptance of kidney or liver transplants by an activation-associated immune mechanism.

Y Yan1, S Shastry, C Richards, C Wang, D G Bowen, A F Sharland, D M Painter, G W McCaughan, G A Bishop.   

Abstract

Donor leukocytes play a dual role in rejection and acceptance of transplanted organs. They provide the major stimulus for rejection, and their removal from the transplanted organ prolongs its survival. Paradoxically, administration of donor leukocytes also prolongs allograft survival provided that they are administered 1 wk or more before transplantation. Here we show that administration of donor leukocytes immediately after transplantation induced long-term acceptance of completely MHC-mismatched rat kidney or liver transplants. The majority of long-term recipients of kidney transplants were tolerant of donor-strain skin grafts. Acceptance was associated with early activation of recipient T cells in the spleen, demonstrated by a rapid increase in IL-2 and IFN-gamma at that site followed by an early diffuse infiltrate of activated T cells and apoptosis within the tolerant grafts. In contrast, IL-2 and IFN-gamma mRNA were not increased in the spleens of rejecting animals, and the diffuse infiltrate of activated T cells appeared later but resulted in rapid graft destruction. These results define a mechanism of allograft acceptance induced by donor leukocytes that is associated with activation-induced cell death of recipient T cells. They demonstrate for the first time that posttransplant administration of donor leukocytes leads to organ allograft tolerance across a complete MHC class I plus class II barrier, a finding with direct clinical application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290811     DOI: 10.4049/jimmunol.166.8.5258

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Engraftment of syngeneic and allogeneic endothelial cells, hepatocytes and cholangiocytes into partially hepatectomized rats previously treated with mitomycin C.

Authors:  Kate E Brilliant; David R Mills; Helen M Callanan; Douglas C Hixson
Journal:  Transplantation       Date:  2009-08-27       Impact factor: 4.939

3.  Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation.

Authors:  Hideyoshi Toyokawa; Atsunori Nakao; Robert J Bailey; Michael A Nalesnik; Takashi Kaizu; Jerome L Lemoine; Atsushi Ikeda; Koji Tomiyama; Glenn D Papworth; Leaf Huang; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Liver Transpl       Date:  2008-03       Impact factor: 5.799

4.  Functional changes of dendritic cells derived from allogeneic partial liver graft undergoing acute rejection in rats.

Authors:  Ming-Qing Xu; Zhen-Xiang Yao
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

Review 5.  The CD8 T-cell response during tolerance induction in liver transplantation.

Authors:  Yik Chun Wong; Geoffrey W McCaughan; David G Bowen; Patrick Bertolino
Journal:  Clin Transl Immunology       Date:  2016-10-14

Review 6.  Immunological Consequences of In Utero Exposure to Foreign Antigens.

Authors:  Jeng-Chang Chen
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 7.  Transplant Tolerance, Not Only Clonal Deletion.

Authors:  Bruce M Hall; Nirupama D Verma; Giang T Tran; Suzanne J Hodgkinson
Journal:  Front Immunol       Date:  2022-04-21       Impact factor: 8.786

Review 8.  Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?

Authors:  Eithne C Cunningham; Alexandra F Sharland; G Alex Bishop
Journal:  Clin Dev Immunol       Date:  2013-11-06

Review 9.  Induction Phase of Spontaneous Liver Transplant Tolerance.

Authors:  Geoffrey W McCaughan; David G Bowen; Patrick J Bertolino
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.